This trial is conducted in Europe. The aim of this trial is to demonstrate a difference between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
35
One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Novo Nordisk Investigational Site
Neuss, Germany
Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes
Maximum GIR value
Time to maximum GIR value
Area under the GIR profile
Cmax, maximum insulin aspart concentration
Area under the insulin aspart concentration curve
tmax, the time to maximum insulin aspart concentration
t½, terminal half-life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days